←
Alex Wyatt1,284 posts
Alex Wyatt avatar✓

Alex Wyatt ✓

@ResearchWyatt

Prostate cancer genomics and ctDNA. Associate Prof for a precision oncology team @VanProstateCtr @UBCmedicine @BCCancer_GSC

◷ Joined August 2017▧ 192 Photos and videos
Michael Hofman avatar
⟳ Alex Wyatt retweeted
Michael Hofman@DrMHofman·1 Jun 2025

Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair response genes PPM1D, TP53, ATM, and CHEK2. ■ Clinical significance unclear but may become more relevant as radioligand therapy moves into earlier lines of treatment @ResearchWyatt @AzadOncology

Post attachmentPost attachment
UroToday.com avatar
⟳ Alex Wyatt retweeted
UroToday.com@urotoday·30 May 2025

Substudy C of the Canadian Cancer Trials Group IND.234 PC_BETS—A phase II study of darolutamide selected by androgen-receptor ctDNA in patients with #mCRPC after prior ARPIs Study shows darolutamide has modest efficacy in #mCRPC post-ARPIs—but ctDNA AR profiling helps select likely responders 🔹 Benefit enriched in: • AR amplification w/ >10 copies • AR mutations (L702H, T878A) • SPOP mutations 📉 Biomarker-negative patients saw little benefit 💊 Darolutamide well-tolerated #ReadNow > bit.ly/3SXuAey @michael_ong @ResearchWyatt @cancersociety @sebastienhotte @CDNCancerTrials

Post attachment
Michael Hofman avatar
⟳ Alex Wyatt retweeted
Michael Hofman@DrMHofman·27 May 2025

Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative biomarkers (SUVmean) are additive 🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire Online at @NatureMedicine nature.com/articles/s41591-0… @ANZUPtrials #TheraP @MovemberAUS @PCFA Support by @PCF_Science Challenge Award @ResearchWyatt @AzadOncology @Prof_IanD

Post attachmentPost attachmentPost attachmentPost attachment
Edmond Kwan avatar
⟳ Alex Wyatt retweeted
Edmond Kwan@EdmondMKwan·27 May 2025

So many to thank that played an outsized role in making this possible. Special mention to close friends in @ResearchWyatt lab for keeping me level-headed for last 2-3 years, @VanProstateCtr for providing a home away from home, @ANZUPtrials for bridging my return home through Synchrony Fellowship, and @PCF_Science for inspiring our team through a Challenge Award. Deeply thankful to the patients whose contributions continue to drive discoveries like this. Really the dream start as I build my team at @easternhealthau @Monash_FMNHS @MonashBDI @EHCSMonash🧵10/10 - end

Post attachment
Michael Hofman avatar
⟳ Alex Wyatt retweeted
Michael Hofman@DrMHofman·22 Feb 2025

Hot of the press in @JournalofNucMed ... with 10 years experience in Lutetium-177 PSMA radioligand therapy we describe a 1.3% incidence of myelodysplasia. We deep dive on each case with remarkable findings. One patient who participated in the @ANZUPtrials #TheraP trial had blood frozen prior to treatment. Analysis by @ResearchWyatt @EdmondMKwan identified a specific "at-risk" mutation that was present prior to Lu-PSMA. jnm.snmjournals.org/content/… Shout-out to first author @pros_tic fellow Dr Michal Eifer @sheba_medical and co-authors @ButeauJames @AzadOncology @drlouiseemmett @LouiseKostos @liz_medhurst @SandhuShahneen @PCF_Science

Post attachmentPost attachment
Yüksel Ürün avatar
⟳ Alex Wyatt retweeted
Yüksel Ürün@DrYukselUrun·14 Feb 2025

🔥 ctDNA Testing: Smoke Detector vs. Fire Investigation! 🔥 Nice analogy by @ResearchWyatt 🧬🧬🧬Not all ctDNA tests serve the same purpose! Some detect cancer early (like a smoke detector), while others characterizetumor properties to guide treatment (like a fire investigation). Choosing the right test matters! @isliquidbiopsy @ChristianRolfo @UmbertoMalapel1 @ElJanLe #GU25 #cancer #oncology #LiquidBiopsy @asco @oncoalert @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @DrChoueiri @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @OncoBellmunt @sonpavde @MattGalsky @tompowles1 @Uromigos @kalasri3 @TiansterZhang @AndreaNecchi @ERPlimackMD @OncBrothers

Post attachmentPost attachmentPost attachmentPost attachment
Alex Wyatt avatar
Alex Wyatt@ResearchWyatt·22 Jan 2025

Thank you to funders, especially to @tfri_research for supporting this prostate cancer research in my team! We're applying cfChIP-seq to more patient samples in 2025 including a big expansion to advanced bladder cancer via generous grant support from @BladderCancerUS

Alex Wyatt avatar
Alex Wyatt@ResearchWyatt·22 Jan 2025

I'm not sure cfChIP-seq is *immediately* clinic-ready partly because low ctDNA% samples are much less informative, but I’m excited to see where M Freedman, @jberchuck, @SylvanBacaLab, and other pioneers will take this emerging technology in prostate cancer!

Alex Wyatt avatar
Alex Wyatt@ResearchWyatt·22 Jan 2025

At the moment, I think of this technique (plasma cfChIP-seq) as a tool to help us learn about metastatic biology, treatment resistance and therapeutic vulnerabilities - in 1000s of patients and in a way that wasn’t previously possible in a bone-predominant cancer.

Alex Wyatt avatar
Alex Wyatt@ResearchWyatt·22 Jan 2025

What we can learn from histone modifications on prostate cancer ctDNA? Here’s our collaboration with David Takeda (NIH) where we performed cfChIP-seq for H3K4me2 on ctDNA from an aggressive set of mCRPC. Insights into patient-to-patient disease biology! aacrjournals.org/cancerres/a…

Post attachmentPost attachment